These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8740082)

  • 1. Inhibition of lipid hydroperoxidation of low density lipoprotein by the Ca(2+)-channel and alpha 1-adrenoceptor antagonist monatepil maleate.
    Hayashi K; Kuga Y; Nomura S; Okura Y; Tanaka K; Yasunobu Y; Nomura K; Shingu T; Kuwashima J; Kajiyama G
    Arzneimittelforschung; 1996 Apr; 46(4):378-81. PubMed ID: 8740082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-atherosclerotic and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese Macaca fuscata monkeys.
    Miyazaki M; Hosoki K; Okunishi H; Ishii K; Ikeno A; Okazaki Y
    Arzneimittelforschung; 1994 Mar; 44(3):288-97. PubMed ID: 8192692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on calcium antagonistic and alpha 1-adrenergic receptor blocking activities of monatepil maleate, its metabolites and their enantiomers.
    Honda Y; Masuda Y; Yoshida T; Sato F; Kurokawa M; Hosoki K
    Arzneimittelforschung; 1995 Oct; 45(10):1057-60. PubMed ID: 8595057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative contribution of alpha 1-adrenoceptor blocking activity to the hypotensive effect of the novel calcium antagonist monatepil.
    Sugimoto T; Hosoki K; Karasawa T
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):55-60. PubMed ID: 7564365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of monatepil maleate, a new Ca2+ channel antagonist with alpha1-adrenoceptor antagonistic activity, on cholesterol absorption and catabolism in high cholesterol diet-fed rabbits.
    Ikeno A; Sumiya T; Minato H; Fujitani B; Masuda Y; Hosoki K; Kurono M; Yasuba M
    Jpn J Pharmacol; 1998 Nov; 78(3):303-12. PubMed ID: 9869264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals.
    Miyazaki M
    Am J Hypertens; 1994 Oct; 7(10 Pt 2):131S-40S. PubMed ID: 7826563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the new calcium antagonist monatepil on cardiac function and myocardial oxygen supply and demand in animals.
    Kataoka T; Nose I; Honda Y; Yamada T; Hatano N; Masuda Y; Hosoki K; Karasawa T
    Arzneimittelforschung; 1993 Dec; 43(12):1303-9. PubMed ID: 8141817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo electrocardiographic evaluation of the novel calcium antagonist monatepil on cardiac conduction system.
    Nose I; Kataoka T; Honda Y; Yamada T; Ikeno A; Fukuya F; Minato H; Takeyama K; Hosoki K; Karasawa T
    Arzneimittelforschung; 1993 Jul; 43(7):722-8. PubMed ID: 8369002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effects of AJ-2615, a new calcium antagonist with alpha 1-adrenergic blocking activity in experimental hypertensive animals.
    Ikeno A; Nose I; Fukuya F; Minato H; Takeyama K; Hosoki K; Karasawa T
    J Cardiovasc Pharmacol; 1993 May; 21(5):815-21. PubMed ID: 7685454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of monatepil, a novel calcium antagonist with alpha 1-adrenergic blocking activity, on the low-density lipoprotein receptor in human skin fibroblasts.
    Matsunaga A; Inoue T; Koga T; Mori K; Kugi M; Sasaki J; Arakawa K
    Cardiovasc Drugs Ther; 1997 Dec; 11(6):747-50. PubMed ID: 9512869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lipid peroxidation products and antioxidants on the formation of probucol radical in low density lipoproteins.
    Shumaev KB; Ruuge EK; Dmitrovsky AA; Bykhovsky VYa ; Kukharchuk VV
    Biochemistry (Mosc); 1997 Jun; 62(6):657-60. PubMed ID: 9284547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive effect of a new calcium antagonist, monatepil, on drug-induced ischaemic electrocardiographic changes in rats.
    Yamamoto T; Nakatsuji K; Hosoki K; Karasawa T
    Clin Exp Pharmacol Physiol; 1993 Nov; 20(11):673-8. PubMed ID: 8306512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B carbonyl formation is enhanced by lipid peroxidation during copper-mediated oxidation of human low-density lipoproteins.
    Yan LJ; Lodge JK; Traber MG; Packer L
    Arch Biochem Biophys; 1997 Mar; 339(1):165-71. PubMed ID: 9056246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of hepatic LDL receptor gene expression by monatepil, a novel calcium antagonist, in high cholesterol diet-fed Japanese monkeys.
    Notake M; Kondo Y; Nomura H; Nakano K; Hosoki K; Miyazaki M
    Am J Hypertens; 1994 Nov; 7(11):1026-30. PubMed ID: 7848617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrovascular selectivity and vasospasmolytic action of the novel calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate in isolated cerebral arteries of the rabbit and dog.
    Minato H; Hashizume M; Masuda Y; Fujitani B; Hosoki K
    Arzneimittelforschung; 1997 Apr; 47(4):339-46. PubMed ID: 9150852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of monatepil maleate on acyl-CoA:cholesterol acyltransferase activity in the liver of cholesterol-fed Japanese monkeys.
    Sumiya T; Ikeno A; Kato H; Fujitani B; Masuda Y; Hosoki K; Miyazaki M
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):779-85. PubMed ID: 9234833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant effect of probucol on RO2*/O2(*-)-induced peroxidation of human low-density lipoproteins.
    Bonnefont-Rousselot D; Segaud C; Jore D; Delattre J; Gardès-Albert M
    Radiat Res; 1999 Mar; 151(3):343-53. PubMed ID: 10073673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiperoxidative actions of calcium antagonists and atherogenesis.
    Henry PD
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S6-10. PubMed ID: 1723459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probucol inhibits lipid peroxidation of macrophage and affects its secretory properties.
    Liu GX; Ou DM; Liu JH; Huang HL; Liao DF
    Acta Pharmacol Sin; 2000 Jul; 21(7):637-40. PubMed ID: 11360673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cu(I) availability paradoxically antagonizes antioxidant consumption and lipid peroxidation during the initiation phase of copper-induced LDL oxidation.
    Bagnati M; Bordone R; Perugini C; Cau C; Albano E; Bellomo G
    Biochem Biophys Res Commun; 1998 Dec; 253(2):235-40. PubMed ID: 9878521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.